Shanxi Zhendong Pharmaceutical(300158.SZ): Application for new drug of Lactobacillus dual live capsules for vaginal use accepted

15:52 10/12/2025

Fendong Pharmaceuticals (300158.SZ) announced that the New Drug Application (NDA) for the core product "Lactobacillus Bifidobacteria Dual Active Capsules for Vaginal Use" of Guangdong Longchuang Ji pharmaceutical Industry Co., Ltd. (referred to as "Longchuang Ji pharmaceutical Industry"), in which the company holds a stake, has been accepted by the China National Medical Products Administration Drug Evaluation Center (CDE).

Shanxi Zhendong Pharmaceutical (300158.SZ) announced that the new drug application (NDA) for the core product "Vaginal Lactobacillus Duo Live Capsules" of Guangdong Longchuang Pharmaceutical Co., Ltd. (referred to as "Longchuang Medical") in which the company holds a stake has been accepted by the China National Medical Products Administration Drug Evaluation Center (CDE). This drug is a compound preparation, with the main components being Lactobacillus bulgaricus and Lactobacillus rhamnosus, used for the restoration of vaginal flora and the treatment of bacterial vaginosis.

MOBI DEV (00947) spent 582 Hong Kong dollars to repurchase 4000 shares on December 10th.

Xuelong Group (603949.SH) intends to invest in establishing a subsidiary to extend its layout in the die casting product sector.

Shanghai Pharmaceuticals Holding (02607) will pay a mid-term dividend of 1.2 yuan for every 10 shares on February 6, 2026.

MOBI DEV (00947) spent 582 Hong Kong dollars to repurchase 4000 shares on December 10th.

Xuelong Group (603949.SH) intends to invest in establishing a subsidiary to extend its layout in the die casting product sector.

Shanghai Pharmaceuticals Holding (02607) will pay a mid-term dividend of 1.2 yuan for every 10 shares on February 6, 2026.